WebDoctor Encyclopedia

Soft-tissue sarcomas

Epithelioid sarcoma

Epithelioid sarcoma is a rare soft-tissue cancer that usually starts as a firm lump on the hand or forearm of a young adult. It often recurs locally and can spread to lymph nodes and lungs.

Medically reviewed Last reviewed October 17, 2026

What is epithelioid sarcoma?

Epithelioid sarcoma is a rare cancer of the soft tissues. It most often starts as a small, firm lump in the fingers, hand or forearm of a teenager or young adult.

Under the microscope, the cancer cells look like epithelial cells, the cells that line the skin and organs. That is where the name “epithelioid” comes from. In fact, it is a sarcoma, a cancer of connective tissue.

Epithelioid sarcoma is often mistaken at first for a harmless condition, such as a wart, an infected nodule, a ganglion or a granuloma. This can delay the diagnosis by months or years.

It tends to come back in the same area after surgery. It can also spread along tendons, to nearby lymph nodes and to the lungs.

Almost all epithelioid sarcomas have lost a protein called INI1 (SMARCB1). This discovery led to the first targeted drug for the disease, tazemetostat.

1. Key facts at a glance

Feature Details
How common Fewer than 1% of soft-tissue sarcomas
Typical age Classic type: mostly 10-35. Proximal type: usually older, around 20-60
Sex More common in males
Main sites Classic type: fingers, hand, wrist, forearm, lower leg and foot. Proximal type: pelvis, groin, buttock, genital area and trunk
Key gene change Loss of SMARCB1 (INI1) in over 90%
Spread Local spread along fascia and tendons; lymph nodes; lungs
Main treatments Wide surgery, radiotherapy, tazemetostat and chemotherapy for advanced disease
Outlook About half to two-thirds alive at 5 years; better for small, distal tumours

2. Types of epithelioid sarcoma

Feature Classic (distal) type Proximal type
Who Adolescents and young adults Mostly middle-aged adults
Where Hands, fingers, forearms, feet Pelvis, perineum, genital area, groin, trunk
Appearance Small, firm nodules, sometimes ulcerated Larger, deep masses
Cells Nodules of cells with central necrosis, which can look like a granuloma Large cells with a “rhabdoid” look
Behaviour Slow growth, frequent local recurrence More aggressive, with earlier spread
INI1 loss Yes Yes

3. Causes and risk factors

The cause is not known in most people.

Factor Notes
SMARCB1 (INI1) loss An acquired change in the tumour that switches off a “brake” on cell growth. It also makes the cells depend on a protein called EZH2, which tazemetostat blocks
Injury Many people remember an injury to the area, but injury is not thought to cause the cancer; it may simply draw attention to the lump
Inherited risk Not usually inherited

4. How does it look?

4.1 On the skin and under it

Feature What it looks or feels like
Lump A small, firm, painless nodule under the skin, often on a finger, the palm or forearm
Several nodules A chain of nodules along a tendon or the forearm, as the tumour spreads along tissue planes
Ulcer The skin over the lump may break down into a non-healing ulcer that can look like an infection
Skin colour Usually skin-coloured; sometimes red, purple or crusted
Proximal type A deep, larger swelling in the groin, buttock or genital area

4.2 On scans

Test Typical findings
MRI A soft-tissue mass, often spreading along tendons or fascia, with enhancement after contrast; there may be several nodules
Ultrasound A solid nodule, often used first
CT chest Looks for lung spread
PET-CT May be used to look for lymph node and distant spread

4.3 Under the microscope

Feature Description
Pattern Nodules of plump cells, often with dead tissue in the centre; this can look like a granuloma
Cells Epithelial-like cells with pink cytoplasm, mixed with spindle-shaped cells
Markers Positive for cytokeratins and EMA (like carcinoma), often CD34 and ERG
INI1 stain Loss of INI1 in the tumour cell nuclei in over 90% of cases

5. Symptoms

Symptom Details
A lump The commonest sign; slow-growing and usually painless
Non-healing sore An ulcer over the lump that does not respond to antibiotics or creams
Several lumps New nodules near the first one, often along the arm or hand
Pain or numbness If the tumour presses on a nerve
Stiffness Reduced movement of a finger or hand
Swollen glands In the elbow, armpit or groin if the cancer has reached lymph nodes
Cough or breathlessness Rare, with lung spread

See a doctor for any lump that is growing, larger than 5 cm, deep, or keeps coming back after removal, or for a sore that will not heal.

5.1 Conditions it can be mistaken for

Condition How it differs
Wart or callus Warts are on the skin surface; epithelioid sarcoma lies under the skin and keeps growing
Ganglion cyst A ganglion is fluid-filled on ultrasound; epithelioid sarcoma is solid
Infection or abscess Infections usually improve with antibiotics or drainage; the sarcoma does not
Granuloma annulare or rheumatoid nodule Biopsy can look similar, but INI1 staining shows loss in epithelioid sarcoma
Giant cell tumour of tendon sheath Also a lump on a finger, but benign and with a different appearance on MRI and biopsy
Carcinoma or melanoma Can share markers, but the pattern of stains and INI1 loss point to epithelioid sarcoma

Because of these look-alikes, any hand or forearm lump that grows or returns after removal should be checked with imaging and a biopsy reviewed by a sarcoma pathologist.

6. Diagnosis

Step Purpose
MRI Before any biopsy, to see the extent of the tumour
Core needle biopsy At or in discussion with a sarcoma centre, planned so that the biopsy track can be removed later
Pathology with INI1 stain Confirms the diagnosis and separates it from carcinoma, melanoma and benign granulomas
CT chest Checks for lung spread
Lymph node assessment Ultrasound, PET-CT, or sometimes sentinel lymph node biopsy, as nodal spread is more common than in most sarcomas

Lumps that are removed without planning (“whoops” excisions) often leave tumour behind. A further, wider operation is then usually needed.

6.1 Your care team

Team member Role
Sarcoma surgeon or hand surgeon Plans and performs the operation, often with a plastic surgeon for reconstruction
Sarcoma pathologist Confirms the diagnosis with special stains, including INI1
Radiologist Performs and reads MRI, CT and guided biopsies
Clinical oncologist Plans radiotherapy
Medical oncologist Advises on chemotherapy, tazemetostat and trials
Specialist nurse Your main contact for questions and support
Hand therapist or physiotherapist Helps restore movement and strength after treatment

All these specialists meet in a multidisciplinary team (MDT) meeting to agree the best plan for each person.

7. Treatment

Treatment should be led by a specialist sarcoma team, in line with ESMO-EURACAN-GENTURIS guidance.

7.1 Localised disease

Treatment Details
Wide surgical excision Removing the tumour with a margin of healthy tissue is the main treatment
Limb- and hand-sparing surgery Usually possible; reconstruction by plastic or hand surgeons may be needed
Amputation Occasionally needed, for example of a finger, when a clear margin cannot otherwise be obtained
Radiotherapy Before or after surgery, especially for larger tumours or close margins; reduces local recurrence
Lymph node surgery If nodes are involved
Chemotherapy Sometimes considered for large or high-risk tumours, case by case

7.2 Advanced or metastatic disease

Treatment Evidence and key points
Tazemetostat An EZH2 inhibitor tablet for tumours with INI1 loss. In a phase 2 trial, about 15% had tumour shrinkage and many more had stable disease, often with good tolerance. It received accelerated US approval in 2020
Anthracycline-based chemotherapy Doxorubicin, with or without ifosfamide; responses in about 1 in 5 in an international series
Gemcitabine-based chemotherapy Similar response rates
Pazopanib Little activity in epithelioid sarcoma in reported series
Radiotherapy and surgery for metastases To control specific sites or relieve symptoms
Immunotherapy and clinical trials Being studied; INI1-deficient tumours are a research focus

7.3 Side effects of treatment

Treatment Common side effects
Hand and arm surgery Reduced grip, stiffness or numbness; hand therapy helps
Radiotherapy Skin redness, later stiffness, swelling or fibrosis
Chemotherapy Hair loss, nausea, low blood counts, infection risk, tiredness
Tazemetostat Tiredness, nausea, pain, low appetite; a small risk of second blood cancers is monitored

7.4 Treatment for children and adolescents

Epithelioid sarcoma is one of the non-rhabdomyosarcoma soft-tissue sarcomas of childhood. Young patients are treated in paediatric or teenage and young adult sarcoma units, often following international study group protocols.

Point Details
Surgery Remains the main treatment, aiming for clear margins while protecting growth and function
Radiotherapy Used selectively, as it can affect bone growth and cause long-term stiffness
Chemotherapy Considered for large, high-grade or metastatic tumours
Tazemetostat Approved in the United States for patients aged 16 and over with advanced disease; younger patients may access it through trials

8. Outlook (prognosis)

Factor Effect on outlook
Classic distal type, small tumour, clear margins Best outlook
Proximal type Worse outlook
Size over 5 cm, deep tumour, necrosis Worse
Lymph node or lung spread Worse
Repeated local recurrence Raises the risk of distant spread

Overall, about 50-70% of people are alive at 5 years, but late recurrence can occur, so long follow-up is needed.

Recurrences can appear many years after treatment. Local recurrence is particularly common if the first operation did not achieve clear margins, which is one reason why surgery at a specialist sarcoma centre matters so much.

9. Follow-up

What How often
Clinic visit and examination of the scar and nodes Every 3-4 months for 2-3 years, then every 6 months to 5 years, then yearly
MRI of the original site Regularly in the first years
CT chest Every 3-6 months at first
Length of follow-up At least 10 years

10. Living with epithelioid sarcoma

Topic Practical advice
Hand function Physiotherapy and occupational therapy help recovery after hand or arm surgery
Checking yourself Learn how your scar and nearby lymph nodes feel, and report new lumps early
Young people Teenage and young adult cancer teams offer support with education, work and fertility
Support Sarcoma charities provide information and connect people with rare sarcomas

11. Frequently asked questions

Question Answer
Is it a skin cancer? No. It is a soft-tissue sarcoma that often lies just under the skin
Why was it first thought to be harmless? Small nodules and ulcers look like common benign problems. Its rarity also makes it easy to miss
Will I lose my hand? Most people keep their hand or limb. Amputation of a finger or part of a limb is occasionally needed for clear margins
What does INI1 loss mean? The tumour has lost a growth-controlling protein. This is used for diagnosis and allows treatment with tazemetostat
Is it inherited? Usually not
Can I keep working or studying? Many people do, with time off around surgery and radiotherapy. Hand surgery may need several weeks of recovery before heavy use
Will radiotherapy affect my hand? It can cause stiffness or tightness of the skin over time. Regular stretching and hand therapy reduce this
What if the lump comes back? Local recurrence can often be treated with more surgery and sometimes radiotherapy. Tell your team about any new lump early

Resources

  1. WHO Classification of Tumours Editorial Board (2020) Soft Tissue and Bone Tumours. 5th edn. Lyon: International Agency for Research on Cancer.
  2. Enzinger, F.M. (1970) ‘Epitheloid sarcoma. A sarcoma simulating a granuloma or a carcinoma’, Cancer, 26(5), pp. 1029-1041.
  3. Guillou, L. et al. (1997) ‘”Proximal-type” epithelioid sarcoma, a distinctive aggressive neoplasm showing rhabdoid features. Clinicopathologic, immunohistochemical, and ultrastructural study of a series’, American Journal of Surgical Pathology, 21(2), pp. 130-146.
  4. Hornick, J.L., Dal Cin, P. and Fletcher, C.D. (2009) ‘Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma’, American Journal of Surgical Pathology, 33(4), pp. 542-550.
  5. Chbani, L. et al. (2009) ‘Epithelioid sarcoma: a clinicopathologic and immunohistochemical analysis of 106 cases from the French sarcoma group’, American Journal of Clinical Pathology, 131(2), pp. 222-227.
  6. Gronchi, A. et al. (2021) ‘Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 32(11), pp. 1348-1365.
  7. Frezza, A.M. et al. (2018) ‘Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma: a multi-institutional case series’, JAMA Oncology, 4(9), e180219.
  8. Gounder, M. et al. (2020) ‘Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study’, The Lancet Oncology, 21(11), pp. 1423-1432.
  9. National Cancer Institute (2026) Adult Soft Tissue Sarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.